Clinical Trial Update: A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous versus intravenous nivolumab in melanoma after complete resection has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2025-02-27